

Claims 1-13 (Canceled).

14. (Currently Amended) AAn isolated polypeptide of up to 15 amino acids in length which includes the sequence WXXWXF (SEQ ID NO:9) where each X is independently any amino acid selected from G, A, I, L, V, S, T, K, R or H, ~~R, H, or F~~.

15. (Previously Added) The polypeptide of claim 14 wherein said sequence is WXXWHF (SEQ ID NO:11); where each X is independently any amino acid selected from G, A, I, L, V, S, T, or R.

16. (Previously Added) The polypeptide of claim 15 wherein said sequence is WVRWHF (SEQ ID NO:2) or a fragment thereof capable of binding to an E2F DNA-binding site.

17. (Currently Amended) ~~The~~AAn isolated polypeptide WVRWHF (SEQ ID NO:2) or a variant thereof, which variant comprises from one to ~~three~~two amino acid substitutions, or three conservative amino acid substitutions, and which is capable of binding to an E2F DNA-binding site.

18. (Previously Added) The polypeptide of claim 14 which inhibits the binding of an E2F protein to an E2F DNA binding site with an *in vitro* IC₅₀ of less than 100μM.

19. (Previously Added) The polypeptide of claim 16 which inhibits the binding of an E2F protein to an E2F DNA binding site with an *in vitro* IC50 of less than 100µM.

20. (Currently Amended) A polypeptide which comprises a first portion which has the amino acid sequence of a polypeptide of up to 15 amino acids in length which includes the sequence WXXWXF (SEQ ID NO:9) where each X is independently any amino acid selected from G, A, I, L, V, S T, K, R, H or F, said polypeptide further comprising a ~~the polypeptide of claim 14 and~~ a second portion, attached to the N- or C-terminus of the first portion, which comprises a sequence of amino acids not naturally contiguous to the first portion, said second portion comprising a membrane translocation sequence.

21. (Currently Amended) A polypeptide which comprises a first portion which has the amino acid sequence of a polypeptide of up to 15 amino acids in length which includes the sequence WXXWXF (SEQ ID NO:9) where each X is independently any amino acid selected from G, A, I, L, V, S T, K, R, H or F, ~~the polypeptide of claim 18 and~~ said polypeptide inhibits the binding of an E2F protein to an E2F binding site with an *in vitro* IC50 of less than 100µM, said polypeptide further comprising a second portion, attached to the N- or C-terminus of the first portion, which comprises a sequence of amino acids not naturally contiguous to the first portion, said second portion comprising a membrane translocation sequence.

22. (Previously Added) A composition comprising the polypeptide of claim 14 in association with a carrier or diluent.

23. (Currently Amended) A composition comprising the polypeptide of claim ~~14~~16 in association with a carrier or diluent.

24. (Currently Amended) A multiple antigen peptide of the structure $\text{Pep}_4\text{-Lys}_2\text{-Lys-X}$, where Pep is a polypeptide of up to 15 amino acids in length which includes the sequence WXXWXF (SEQ ID NO:9) where each X is independently any amino acid selected from G, A, I, L, V, S, T, K, R, H or F, ~~the peptide of claim 14,~~ Lys is lysine and X is a terminal group.

25. (Previously Added) A multiple antigen peptide of the structure $\text{Pep}_4\text{-Lys}_2\text{-Lys-X}$, where Pep is a polypeptide of up to 15 amino acids in length which includes the sequence WVRWHF (SEQ ID NO:2) or a fragment thereof capable of binding to an E2F DNA-binding site, ~~the peptide of claim 16,~~ Lys is lysine and X is a terminal group.

26. (Previously Added) A method of inhibiting the growth of a eukaryotic cell which comprises bringing the cell into contact with the polypeptide of claim 14 under conditions to provide for apoptosis.

27. (Previously Added) A method of inhibiting the growth of a eukaryotic cell which comprises bringing the cell into contact with the polypeptide of claim 16 under conditions to provide for apoptosis.

28. (new) A method of inhibiting the growth of a eukaryotic cell which comprises bringing the cell into contact with the polypeptide of claim 20 under conditions to provide for apoptosis.

29. (new) A method of inhibiting the growth of a eukaryotic cell which comprises bringing the cell into contact with the polypeptide of claim 21 under conditions to provide for apoptosis.

30. (new) A method of inhibiting the growth of a eukaryotic cell which comprises bringing the cell into contact with the polypeptide of claim 24 under conditions to provide for apoptosis.

31. (new) A method of inhibiting the growth of a eukaryotic cell which comprises bringing the cell into contact with the polypeptide of claim 25 under conditions to provide for apoptosis.